The association of Metavert-TSHI and Metavert+IR-TSHI scores with different molecular profiles may open up novel strategies for treating pancreatic cancer, as different cell regulatory mechanisms appear to be susceptible to single agent Metavert (mRNA splicing and DNA repair molecular processes) or to Metavert+IR (regulation of TP53 molecular processes). This evidence concerns the gene TP53 and pancreatic neoplasm.